Physician profile
Richard W Schutzer
NPI 1346331519
$7,439.91
in general payments reported to CMS, 2019-2025
32 companies · $2,779 in 2025
The $2,779 reported for 2025 was more than what 76% of Vascular Surgery providers received nationally (typical 2025 total: $927).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,473 · 2020: $607 · 2021: $492 · 2022: $95.50 · 2023: $231 · 2024: $1,763 · 2025: $2,779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,835 · Travel and Lodging: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,835.44 |
| Travel and Lodging | $1,937.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $2,546.55 | 2019-2025 | Gore Excluder Thoracoabdominal Branch Endoprosthesis, Gore Tag Thoracic Branch Endoprosthesis, Gore Tag Thoracic Endoprosthesis |
| Endologix LLC | $1,743.43 | 2024-2025 | Torus Stent Graft System, Endocross Device, Afx2 Bifurcated Endograft System |
| Cook Medical LLC | $656.47 | 2019-2021 | |
| Musculoskeletal Transplant Foundation INC. | $429.57 | 2020-2021 | |
| Boston Scientific Corporation | $353.96 | 2019-2021 | |
| Smith+Nephew, INC. | $196.16 | 2019-2023 | Grafix Pl |
| Shockwave Medical, INC | $184.96 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Artivion, INC. | $167.29 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Polarityte, INC. | $102.69 | 2019 | |
| Janssen Pharmaceuticals, INC | $88.38 | 2019-2021 | |
| Abbvie INC. | $77.43 | 2021-2022 | |
| Penumbra, INC. | $76.12 | 2020-2024 | Indigo System, Penumbra System |
| Allergan, INC. | $73.92 | 2019-2020 | |
| Convatec INC. | $70.31 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $60.00 | 2020 | |
| Tactile Systems Technology INC | $55.69 | 2019-2022 | |
| Argenx US, INC. | $52.37 | 2022-2023 | Vyvgart |
| Stryker Corporation | $46.68 | 2025 | Clottriever Bold Catheter |
| Grifols USA, LLC | $44.31 | 2022-2024 | Gamunex-C |
| Regeneron Healthcare Solutions, INC. | $38.39 | 2019 | |
| Abbott Laboratories | $29.33 | 2025 | Esprit |
| Ethicon US, LLC | $27.75 | 2023 | Surgiflo Hemostatic Matrix, Surgicel Nu-Knit, Prolene |
| Otter Pharmaceuticals, LLC | $27.58 | 2025 | Sympazan |
| Pfizer INC. | $26.70 | 2024 | |
| Csl Behring | $25.76 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.95 | 2019 | |
| Acell, INC. | $22.49 | 2019 | |
| Tanabe Pharma America, INC. | $19.73 | 2025 | Radicava |
| Bolton Medical INC | $18.05 | 2019 | |
| Neurelis, INC. | $17.00 | 2023 | Valtoco |
| Cardinal Health 200 LLC | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Schutzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.